Abstract: The present disclosure provides a bispecific antibody including a binding domain that binds to CD112R and a binding domain that binds to TIGIT, and the binding domain that binds to CD112R includes: HCDR1, HCDR2 and HCDR3 of the amino acid sequence set forth in SEQ ID NO: 1, and/or LCDR1, LCDR2 and LCDR3 of the amino acid sequence set forth in SEQ ID NO: 2; and the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 are defined according to the Kabat, IMGT, Chothia, AbM or Contact numbering system. The present disclosure further provides a polynucleotide encoding the antibody, an expression vector, a host cell and a method for expressing and purifying the antibody, a pharmaceutical composition including the antibody of the present disclosure, and use of the bispecific antibody for treating cancer.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment (UE) may receive information indicating a condition for a conditional handover, and an indication to communicate on a source cell after transmitting a message on a target cell, associated with the conditional handover, and before receiving an additional message on the target cell. The UE may transmit the message on the target cell responsive to the condition for the conditional handover being satisfied. Numerous other aspects are described.

Abstract: Various aspects of the present disclosure generally relate to wireless communication. In some aspects, a user equipment may determine a transmission frequency for an uplink transmission based at least in part on a reference point for the uplink transmission, the reference point being associated with one of: a satellite that provides a cell covering the user equipment, the satellite being associated with a non-terrestrial network, or a gateway associated with the satellite; and transmit the uplink transmission based at least in part on the transmission frequency. Numerous other aspects are provided.

Abstract: A stable anti-TIGIT antibody pharmaceutical composition and an application thereof. The pharmaceutical composition includes a buffer solution, and an anti-TIGIT antibody or an antigen-binding fragment thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof includes HCDR1, HCDR2, and HCDR3 having amino acid sequences as respectively represented by SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and LCDR1, LCDR2, and LCDR3 having amino acid sequences as respectively represented by SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. The pH of the pharmaceutical composition is about 5.0-6.5.

Abstract: Described herein are therapeutic pH responsive compositions comprising a block copolymer and a therapeutic agent useful for the treatment of cancer.

Abstract: The present disclosure belongs to the field of petroleum engineering, and specifically relates to a subsea Christmas tree re-prediction method integrating Kalman filter and Bayesian network. The subsea Christmas tree re-prediction method integrating Kalman filter and Bayesian network includes three steps: digital twin model establishment, degradation process re-prediction model establishment, and remaining useful life calculation model establishment.

Abstract: An experimentation method for a type I stress intensity factor test considering frost heaving force periodic changes, steps being 1: preparing a specimen, waterjet cutting on the specimen to simulate a non-penetrating rock mass fracture; step 2: vacuum saturating the specimen; step 3: affixing a strain gauge in a non-elastic area at a tip of the specimen; step 4: placing the specimen into a rock mass (1) fracture frost heaving experiment box (5), pressurizing by a pressurizing apparatus (4) balloons on either side of the frost heaving experiment box (5), shutting a valve and removing a pipe, placing the frost heaving experiment box (5) holding the specimen into a water tank, allowing water to immerse the specimen; and step 5: placing the water tank and the frost heaving experiment box (5) holding the specimen together into a high-low temperature alternating experiment box (7) to start a freeze-thaw cycle experiment.

Abstract: The present disclosure belongs to the field of petroleum engineering, and specifically relates to a subsea Christmas tree re-prediction method integrating Kalman filter and Bayesian network. The subsea Christmas tree re-prediction method integrating Kalman filter and Bayesian network includes three steps: digital twin model establishment, degradation process re-prediction model establishment, and remaining useful life calculation model establishment.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: An experimentation method for a type I stress intensity factor test considering frost heaving force periodic changes, steps being 1: preparing a specimen, waterjet cutting on the specimen to simulate a non-penetrating rock mass fracture; step 2: vacuum saturating the specimen; step 3: affixing a strain gauge in a non-elastic area at a tip of the specimen; step 4: placing the specimen into a rock mass (1) fracture frost heaving experiment box (5), pressurizing by a pressurizing apparatus (4) balloons on either side of the frost heaving experiment box (5), shutting a valve and removing a pipe, placing the frost heaving experiment box (5) holding the specimen into a water tank, allowing water to immerse the specimen; and step 5: placing the water tank and the frost heaving experiment box (5) holding the specimen together into a high-low temperature alternating experiment box (7) to start a freeze-thaw cycle experiment.

Abstract: Provided is an application of Butyribacter intestini in the treatment and prevention of obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.

Abstract: The present disclosure provides an effective stress cell for direct measurement of effective stress in saturated soil. The effective stress cell comprises a sensing diaphragm, a porous diaphragm, a connector and a strain sensor. The porous diaphragm allows pore-water to enter the interior space between the sensing diaphragm and the porous diaphragm to provide complete balance of pore-water pressures in the front and back of the sensing diaphragm. Thus, the effective stress cell can directly and accurately measure the effective stress in saturated soil using only one diaphragm at one location without measuring pore-water pressure.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: Provided herein, in one aspect, is hematopoietic lineage cells such as natural killer cells generated in vitro from human pluripotent stem cells (hPSCs) that can be used as a cell source for therapeutics. Methods and compositions for making and using the same are also provided.

Abstract: Described herein are therapeutic pH responsive compositions comprising a block copolymer and a therapeutic agent useful for the treatment of cancer.

Abstract: The present disclosure relates generally to biocompatible nanoparticles, and in particular, neuroprotective nanoparticles comprising ciliary neurotrophic factor and/or oncostatin M. Methods for making and using the same are also provided.

Abstract: Disclosed is a pharmaceutical preparation comprising a CD147 monoclonal antibody, a buffer, a protein protectant and a surfactant. The pharmaceutical preparation can maintain the stability of the CD147 monoclonal antibody over a long period of time. Also disclosed are the use of the pharmaceutical preparation in the preparation of a drug for treating CD147-related diseases, in particular non-small cell lung cancer, and a method for preparing the pharmaceutical preparation.

Abstract: Provided is an application of Butyribacter intestini in the treatment and prevention of obesity and obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.

Abstract: Provided is an application of Butyribacter intestini in the treatment and prevention of obesity-related diseases. Also provided is a composition for the treatment and prevention of obesity and obesity-related diseases.